Vanguard Personalized Indexing Management LLC raised its holdings in Avantor, Inc. (NYSE:AVTR – Free Report) by 4.6% during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 25,440 shares of the company’s stock after purchasing an additional 1,119 shares during the quarter. Vanguard Personalized Indexing Management LLC’s holdings in Avantor were worth $539,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently modified their holdings of the business. Versant Capital Management Inc lifted its position in shares of Avantor by 2,003.6% during the 2nd quarter. Versant Capital Management Inc now owns 1,157 shares of the company’s stock worth $25,000 after buying an additional 1,102 shares during the last quarter. Blue Trust Inc. raised its stake in Avantor by 1,830.3% during the second quarter. Blue Trust Inc. now owns 1,467 shares of the company’s stock worth $31,000 after acquiring an additional 1,391 shares in the last quarter. TFO Wealth Partners LLC lifted its holdings in shares of Avantor by 203,100.0% in the fourth quarter. TFO Wealth Partners LLC now owns 2,032 shares of the company’s stock worth $46,000 after acquiring an additional 2,031 shares during the last quarter. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH acquired a new stake in shares of Avantor in the 1st quarter valued at approximately $93,000. Finally, ORG Partners LLC grew its holdings in shares of Avantor by 5,773.0% during the 2nd quarter. ORG Partners LLC now owns 5,873 shares of the company’s stock valued at $122,000 after purchasing an additional 5,773 shares during the last quarter. Institutional investors own 95.08% of the company’s stock.
Avantor Trading Up 1.5 %
NYSE:AVTR opened at $26.06 on Friday. Avantor, Inc. has a 52 week low of $16.63 and a 52 week high of $28.00. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.05 and a current ratio of 1.59. The firm’s fifty day moving average is $25.34 and its 200-day moving average is $24.37. The firm has a market cap of $17.72 billion, a P/E ratio of 66.74, a P/E/G ratio of 2.71 and a beta of 1.32.
Analyst Upgrades and Downgrades
AVTR has been the subject of several research reports. Wells Fargo & Company began coverage on shares of Avantor in a research note on Tuesday, August 27th. They issued an “overweight” rating and a $30.00 price objective for the company. TD Cowen increased their price target on Avantor from $28.00 to $31.00 and gave the company a “buy” rating in a research note on Monday, July 29th. Stifel Nicolaus boosted their price objective on Avantor from $27.00 to $28.00 and gave the stock a “buy” rating in a research report on Monday, July 29th. Robert W. Baird increased their target price on Avantor from $26.00 to $27.00 and gave the company an “outperform” rating in a research report on Monday, July 29th. Finally, Evercore ISI reduced their price target on Avantor from $28.00 to $27.00 and set an “outperform” rating on the stock in a report on Tuesday, July 2nd. Four equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $27.60.
View Our Latest Stock Report on AVTR
Insider Activity
In related news, CAO Steven W. Eck sold 3,525 shares of the firm’s stock in a transaction that occurred on Thursday, September 5th. The stock was sold at an average price of $25.06, for a total transaction of $88,336.50. Following the completion of the sale, the chief accounting officer now owns 29,544 shares of the company’s stock, valued at $740,372.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.50% of the stock is owned by company insiders.
About Avantor
Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.
Read More
- Five stocks we like better than Avantor
- Comparing and Trading High PE Ratio Stocks
- Rocket Lab Stock Soars: Should Investors Chase the Rally?
- What Do S&P 500 Stocks Tell Investors About the Market?
- KB Home Slips After Earnings: What’s Next for Homebuilders?
- Energy and Oil Stocks Explained
- Micron Stock Soars as AI Demand Fuels Big Q4 Earnings Beat
Want to see what other hedge funds are holding AVTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Avantor, Inc. (NYSE:AVTR – Free Report).
Receive News & Ratings for Avantor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avantor and related companies with MarketBeat.com's FREE daily email newsletter.